Symbolbild · KI-generiert
Omeros Corporation
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Omeros Corporation is a biopharmaceutical company developing medicines for inflammatory, CNS and addiction disorders as well as certain cancers. The company markets the ophthalmic product Omidria and has further candidates in its clinical pipeline, including complement system inhibitors. Its focus areas include rare diseases and immunology.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Omeros Corporation | OMER | NASDAQ | 857 Mio. USD |
| Arbutus Biopharma Corporation | ABUS | NASDAQ | 857 Mio. USD |
| Castle Biosciences, Inc. | CSTL | NASDAQ | 849 Mio. USD |
| Theravance Biopharma, Inc. | TBPH | NASDAQ | 869 Mio. USD |
| Sana Biotechnology, Inc. | SANA | NASDAQ | 871 Mio. USD |
| Annexon, Inc. | ANNX | NASDAQ | 835 Mio. USD |
| Amphastar Pharmaceuticals, Inc. | AMPH | NASDAQ | 879 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.